Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry

Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia

(2010) Charles L. Wiggins et al.   AMERICAN JOURNAL OF MEDICINE

“Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia

(2010) Roberto Latagliata et al.   LEUKEMIA RESEARCH

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

(2008) S. J. Lee et al.   BLOOD

Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase

(2008) H Bittencourt et al.   BONE MARROW TRANSPLANTATION

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

(2008) C M Lucas et al.   LEUKEMIA

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany

(2008) M Rohrbacher et al.   LEUKEMIA